Halozyme Therapeutics Inc. (1HALO)
MTA
Closed
Oct 2, 2026
Day's Range
88.7252 wk Range
48.73Overview - 1HALO - Halozyme Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
11.40B
P/E (Trailing)
‪32.75‬
PEG Ratio
‪0.74‬
Price / Sales (TTM)
‪6.54‬
Price / Book
‪85.50‬
EV / EBITDA
‪12.22‬
Profitability
Gross Margin
‪83.54%‬
Profit Margin
‪24.85%‬
Operating Margin
‪59.80%‬
Return on Assets
‪25.49%‬
Return on Equity
‪173.67%‬
Ownership
Shares Outstanding
114.04M
Float
112.18M
Held by Insiders
‪1.08%‬
Held by Institutions
‪112.16%‬
Price stats
Beta
‪0.87‬
50-Day Avg
‪89.66‬
200-Day Avg
‪67.00‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 1HALO - Halozyme Therapeutics Inc.
Peers - 1HALO - Halozyme Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on MTA.
- 1HALOMTAHalozyme Therapeutics Inc.6.90BMarket Cap+39.83%52-week change32.76P/E (Trailing)‪24.85%‬Profit Margin
- 1VRTXMTAVertex Pharmaceuticals Incorporated Common Stock107.27BMarket Cap+27.72%52-week change30.40P/E (Trailing)‪34.99%‬Profit Margin
- 1REGNMTARegeneron Pharmaceuticals, Inc.73.52BMarket Cap+30.66%52-week change19.47P/E (Trailing)‪27.86%‬Profit Margin
- 1ALNYMTAAlnylam Pharmaceuticals, Inc.45.81BMarket Cap-73.35%52-week change43.84P/E (Trailing)‪16.12%‬Profit Margin
- 1INSMMTAInsmed Incorporated30.28BMarket Cap-19.46%52-week change-16.17P/E (Trailing)‪-76.94%‬Profit Margin
- 1CGMTAThe Carlyle Group Inc.18.64BMarket Cap-40.10%52-week change42.38P/E (Trailing)‪13.01%‬Profit Margin
- 1INCYMTAIncyte Corp.17.89BMarket Cap+32.92%52-week change15.77P/E (Trailing)‪27.70%‬Profit Margin
Profile Summary - 1HALO - Halozyme Therapeutics Inc.
About
Halozyme Therapeutics Inc. is a biopharmaceutical technology platform company specializing in innovative drug delivery solutions. The company focuses on enhancing the administration of biologic and other injectable therapies through its proprietary ENHANZE drug delivery technology, built on the recombinant human…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
